The EURORDIS Open Academy has launched a survey to know more about training needs, such as the reasons for engaging in training, main topics of interest, and the roadblocks that […]
Read More
What does the IMPC do?The IMPC systematically studies the consequences of removing gene function in mice with the aim of learning more about human disease. The project has now generated […]
Read More
The Solve-RD consortium and associated European Solve-RD network, including among others six European Reference Networks, EURORDIS, Orphanet and leading European Rare Disease Clinicians and Researchers in 20 countries, call upon […]
Read More
IRDiRC is thrilled to present a new video from the Interview Series with its members. This month we have in the spotlight David Adams, IRDiRC Diagnostics Scientific Committee (DSC) Chair […]
Read More
Under Horizon Europe, the European Commission together with member states and associated countries decided to implement the Rare Diseases Partnership which brings a unique vision that aims at leaving no […]
Read More
There are over 6,000 different rare diseases identified to date that affect 3.5% – 5.9% of the worldwide population. They have a big impact not only on the person diagnosed, […]
Read More
The Canadian Institute of Health Research – Institute of Genetics is pleased to announce the upcoming funding opportunity “National Pediatric Rare Disease Clinical Trials and Treatment Network”. The specific objectives […]
Read More
The 35th Annual Meeting of EMSOS will take place this year on 10-12 May, 2023, in Brussels (Belgium), and it will join the efforts of all Belgian University Hospitals and […]
Read More
On March 22, 2023, the Canadian Federal Government announced the launch of Canada’s Rare Disease Drug Strategy with a $1.5 billion commitment over three years to “improve access to new […]
Read More
A new network for nurses has been created to exchange skills, knowledge, solve problems and generate new ideas for the rare disease community. The first meeting to develop the network […]
Read More